Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats

References

• Adderley SR, Fitzgerald DJ. 1999. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases ½-mediated induction of cyclooxygenase-2. J Biol Chem 274:5038–5046.
   PubMed Web of Science ®Google Scholar
• Alkreathy H, Damanhouri ZA, Ahmed N, Slevin M, Ali SS, Osman AM. 2010. Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 48:951–956.
   PubMed Web of Science ®Google Scholar
• Al-Majed AA, Al-Yahya AA, Asiri Y, Al-Gonaiah MA, Mostafa AM. 2004. Nimesulide prevents oxidative stress damage following transient forebrain ischemia in the rat hippocampus. Res Commun Mol Pathol Pharmacol 115-116:49–62.
   PubMedGoogle Scholar
• Bose R, Sutherland GR, Pinsky C. 1989. Biological and methodological implications of prostaglandin involvement in mouse brain lipid peroxidation measurements. Neurochem Res 14:217–220.
   PubMed Web of Science ®Google Scholar
• Breyer MD, Harris RC. 2001. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 10:89–98.
   PubMed Web of Science ®Google Scholar
• Carnieto A Jr, Dourado PM, Luz PL, Chagas AC. 2009. Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (Sao Paulo) 64:245–252.
   PubMed Web of Science ®Google Scholar
• Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X, Kennedy C, Breyer MD, Moeckel GW, Harris RC. 2007. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 18:551–559.
   Google Scholar
• Delgado RM 3rd, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK, Aleksic N, Sivasubramanian N, McKay K, Mann DL, Willerson JT. 2004. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 109:1428–1433.
   Google Scholar
• Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C; European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods. 2001. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21:15–23.
   PubMed Web of Science ®Google Scholar
• Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. 2000. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 275:11750–11757.
   PubMed Web of Science ®Google Scholar
• Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. 2001. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585–590.
   PubMed Web of Science ®Google Scholar
• Elberry AA, Abdel-Naim AB, Abdel-Sattar EA, Nagy AA, Mosli HA, Mohamadin AM, Ashour OM. 2010. Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 48:1178–1184.
   PubMed Web of Science ®Google Scholar
• Fahmi H, He Y, Zhang M, Martel-Pelletier J, Pelletier JP, Di Battista JA. 2001. Nimesulide reduces interleukin-1β-induced cyclooxygenase-2 gene expression in human synovial fibroblasts. Osteoarthr Cartil 9:332–340.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, O’Connor A, Gallagher WM, Lenihan CR, Garvey JF, Howell K, Fallon PG, Cummins EP, Taylor CT. 2011. An intact canonical NF-?B pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 186:1091–1096.
   Google Scholar
• Gambaro G, Perazella MA. 2003. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253:643–652.
   PubMed Web of Science ®Google Scholar
• Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB. 2004. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 53:141–150.
   PubMed Web of Science ®Google Scholar
• Gottlieb S. 2001. COX 2 inhibitors may increase risk of heart attack. BMJ 323:471.
   PubMed Web of Science ®Google Scholar
• Hemler M, Lands WE. 1976. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 251:5575–5579.
   PubMed Web of Science ®Google Scholar
• Hla T, Neilson K. 1992. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384–7388.
   PubMed Web of Science ®Google Scholar
• Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S. 2009. Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 187:40–44.
   PubMedGoogle Scholar
• Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. 2009. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 60:373–381.
   PubMed Web of Science ®Google Scholar
• Kalonia H, Kumar P, Kumar A, Nehru B. 2010. Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. Neurotoxicology 31:195–203.
   Google Scholar
• Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. 2001. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3:135–145.
   PubMed Web of Science ®Google Scholar
• LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. 2004. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286:H1416–H1424.
   Google Scholar
• Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. 2007. Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest 87:440–455.
   Google Scholar
• Mihara M, Uchiyama M. 1978. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271–278.
   PubMed Web of Science ®Google Scholar
• Miller B, Patel VA, Sorokin A. 2006. Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). J Am Soc Nephrol 17:977–985.
   PubMed Web of Science ®Google Scholar
• Miyata S, Takemura G, Kosai K, Takahashi T, Esaki M, Li L, Kanamori H, Maruyama R, Goto K, Tsujimoto A, Takeyama T, Kawaguchi T, Ohno T, Nishigaki K, Fujiwara T, Fujiwara H, Minatoguchi S. 2010. Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am J Pathol 176:687–698.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pepine C, Willerson JT. 2002. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 106:167–169.
   PubMed Web of Science ®Google Scholar
• Rivera E. 2003. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8 Suppl 2:3–9.
   Google Scholar
• Saad SY, Najjar TA, Al-Rikabi AC. 2001. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 43:211–218.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD. 2000. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 275:6628–6635.
   PubMed Web of Science ®Google Scholar
• Simunek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. 2009. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154–171.
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. 1998. Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905.
   PubMed Web of Science ®Google Scholar
• Taskin E, Ozcan K, Canacankatan N, Satar M, Yapicioglu HY, Erdogan S. 2009. The effects of indomethacin on caspases, glutathione level and lipid peroxidation in the newborn rats with hypoxic-ischemic cerebral injury. Brain Res 1289:118–123.
   PubMedGoogle Scholar
• Wu HT, Chen W, Cheng KC, Yeh CH, Shen KH, Cheng JT. 2010. Indomethacin activates peroxisome proliferator-activated receptor ? to improve insulin resistance in cotton pellet granuloma model. Horm Metab Res 42:775–780.
   Google Scholar
• Xie W, Fletcher BS, Andersen RD, Herschman HR. 1994. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol Cell Biol 14:6531–6539.
   PubMed Web of Science ®Google Scholar
• Ye W, Zhang H, Hillas E, Kohan DE, Miller RL, Nelson RD, Honeggar M, Yang T. 2006. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 290:F542–F549.
   PubMed Web of Science ®Google Scholar